EA202190576A1 - Полиморфные соединения и их применение - Google Patents

Полиморфные соединения и их применение

Info

Publication number
EA202190576A1
EA202190576A1 EA202190576A EA202190576A EA202190576A1 EA 202190576 A1 EA202190576 A1 EA 202190576A1 EA 202190576 A EA202190576 A EA 202190576A EA 202190576 A EA202190576 A EA 202190576A EA 202190576 A1 EA202190576 A1 EA 202190576A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
polymorphic compounds
compounds
polymorphic
stroke
Prior art date
Application number
EA202190576A
Other languages
English (en)
Russian (ru)
Inventor
Расселл Бёрч Поу
Дэвид Т. Джонаитис
Лиза Мишель Грув
Original Assignee
Астросайт Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астросайт Фармасьютикалс, Инк. filed Critical Астросайт Фармасьютикалс, Инк.
Publication of EA202190576A1 publication Critical patent/EA202190576A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EA202190576A 2018-09-26 2019-09-26 Полиморфные соединения и их применение EA202190576A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736979P 2018-09-26 2018-09-26
PCT/US2019/053076 WO2020069068A1 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Publications (1)

Publication Number Publication Date
EA202190576A1 true EA202190576A1 (ru) 2021-09-03

Family

ID=69885558

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190576A EA202190576A1 (ru) 2018-09-26 2019-09-26 Полиморфные соединения и их применение

Country Status (12)

Country Link
US (2) US10765693B2 (enExample)
EP (1) EP3856741A4 (enExample)
JP (2) JP2022502405A (enExample)
KR (1) KR20210093864A (enExample)
CN (1) CN112930349A (enExample)
AU (1) AU2019346585B2 (enExample)
BR (1) BR112021005290A2 (enExample)
CA (1) CA3113250A1 (enExample)
EA (1) EA202190576A1 (enExample)
IL (1) IL281718A (enExample)
MX (1) MX2021003515A (enExample)
WO (1) WO2020069068A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
IL310045A (en) 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
KR20240122782A (ko) * 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7087589B2 (en) * 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006091905A1 (en) * 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
EP2049127B1 (en) 2006-05-23 2014-11-26 University of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
CN101925610A (zh) 2007-11-23 2010-12-22 巴尔-伊兰大学 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
EP2331542B1 (en) 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
US8822434B2 (en) 2010-02-22 2014-09-02 The University Of Connecticut Compositions and methods to treat cardiac diseases
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US9963450B2 (en) 2013-11-27 2018-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
HK1247119A1 (zh) 2015-02-04 2018-09-21 贝克心脏与糖尿病研究所 一种治疗方法和用於所述治疗方法中的化合物
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法

Also Published As

Publication number Publication date
NZ774215A (en) 2025-03-28
CA3113250A1 (en) 2020-04-02
JP2022502405A (ja) 2022-01-11
WO2020069068A9 (en) 2020-05-14
KR20210093864A (ko) 2021-07-28
MX2021003515A (es) 2021-05-27
US11324769B2 (en) 2022-05-10
WO2020069068A1 (en) 2020-04-02
AU2019346585B2 (en) 2025-02-27
US20200093848A1 (en) 2020-03-26
JP2024114885A (ja) 2024-08-23
US10765693B2 (en) 2020-09-08
CN112930349A (zh) 2021-06-08
EP3856741A1 (en) 2021-08-04
EP3856741A4 (en) 2022-06-22
AU2019346585A1 (en) 2021-04-29
US20210077518A1 (en) 2021-03-18
IL281718A (en) 2021-05-31
BR112021005290A2 (pt) 2021-06-22

Similar Documents

Publication Publication Date Title
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
EA202190576A1 (ru) Полиморфные соединения и их применение
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
EP4017489C0 (en) DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
EP3784260A4 (en) Compositions for the treatment of skin conditions
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EP3802539C0 (en) NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
EP3807270C0 (en) NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
EP3790563A4 (en) Compositions for the treatment of skin conditions
EP4218626C0 (en) DEVICE FOR THE TREATMENT OF ISCHEMIA
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EP3897626C0 (en) TINOSTAMUSTINE FOR THE TREATMENT OF MULTIPLE MYELOMA
EA202090414A1 (ru) Соединения и их применение
EP3573620A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
EP3709968C0 (de) Emulsionen zur behandlung von schleimhautinfektionen
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
EP4055033A4 (en) Combination therapy to treat brain cancer
EP4426686A4 (en) N,N-DIMETHYLAMPHTAMIN ANALOGUES FOR THE TREATMENT OF CEREBRAL DISORDERS
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.